Month: August 2022

TAIPEI, Taiwan, Aug. 19, 2022 — General Biologicals Corporation (GBC), a Taiwanese In-Vitro Diagnostic (IVD) specializing in Precision Diagnostics was honored with the “2022 HR Asia Best Companies to Work for in Asia”. 

In all, 26,200 employees from 330 Taiwanese companies took part in HR Asia’s proprietary Total Engagement Assessment Model – ranking their own employers on metrics ranging from workplace happiness and team cohesion to employee advocacy and continued job motivation. The top 97 companies who made the cut off point this year are then named HR Asia Best Companies to work for in Asia 2022 for the Taiwanese market.

“HR Asia Best Companies to Work for in Asia is the only award that is judged solely by the nominees’ employees – making this the most transparent award of its kind. Equally important, with 15 markets, and over 400,000 surveys done each year – the program is also the most extensive awards for employee engagement and workplace excellence across the region”, says William Ng, group publisher of Business Media International, the owner of HR Asia.

Mr. Frank Lin, President of GBC, said that the group believes that talents are the cornerstone of the sustainable development of the enterprise. Since its establishment, it has adhered to the value-oriented development of all colleagues and the group, including various company benefits, focusing on the physical and mental health of colleagues, respecting the positions of colleagues in various departments, and maintaining colleagues at any time. Coordinating communication and feedback and encouraging the provision of resources for professional training of talents, etc., this award affirms the Group’s progress towards a happy enterprise and sustainable development goals.

 

About General Biologicals Corporation

Founded in 1984, General Biologicals Corporation (GBC) is a developer and manufacturer of diagnostics and pharmaceutical products headquartered in Taiwan. GBC develops high-quality in-vitro diagnostics for doctors to make clinical decisions in the areas of hepatitis, tumor markers, retrovirus, fertility, thyroid, and steroids. The company also provides anti-bacterial peptides (US FDA Clinical Trial Phase IIb) in the areas of pharmaceutical, cosmetics, and oral products. 

In the first half of 2022, GBC consolidated revenue was NT$226 million, net profit after tax was NT$13.66 million, and after-tax earnings per share (EPS) reached NT$0.23, which benefited from the stable shipment momentum of its COVID-19 testing products orders, and increased sales momentum. GB COVID-19 Antigen Rapid Tests (HOME version) have entered the major drugstores such as Bigtree Pharmacy in Taiwan, and the overall operation has achieved the third-highest level over the same period of the past year.

GBC continues to strive for cooperation opportunities such as testing reagent bids in Taiwan and Southeast Asia, as well as expanding global distribution layout, and improving the production efficiency of its bamboo plant, driving the overall gross profit margin in the first half of 2022 to 58%, compared with 53% in the same period last year increase, and the operating profit margin in the first half of 2022 will also remain at the level of 10%.

Looking forward to the third quarter of 2022, GBC is actively completing the clinical trial of its household version of the saliva antigen rapid screening reagent product, and the target will be delivered in the third quarter. As the coexistence policy with the epidemic has been implemented for a long time, there is still a certain demand for new coronary pneumonia-related testing products, and the group’s hepatitis reagent products have gradually improved the ordering performance, which will help to create a stable momentum for its accurate testing business.

In addition, GBC actively expands business development such as liquid biopsy (CellBio™ – Circulating Tumor Cell) and CDMO (Contract Development Manufacturing Organization). GBC offers its core R&D capability, manufacturing, production, fill-in and product registration as a One-stop service providing customized reagent service solution based on customers’ needs. GBC further stated that the group will continue to strive for cooperation opportunities such as tenders in Taiwan and Southeast Asia, as well as expanding global distribution network.